Company Description
Cytosorbents Corporation engages in the research, development, and commercialization of medical devices with its blood purification technology platform incorporating a proprietary adsorbent and porous polymer technology in the United States, Germany, and internationally.
The company’s flagship product is CytoSorb, an extracorporeal blood purification cartridge for the treatment of massive inflammation, organ failure, cardiothoracic surgery to remove antithrombotic drugs and inflammatory mediators that can lead to postoperative complications, such as severe bleeding, shock, failure to wean from mechanical ventilation, sepsis, and multiple organ failure; DrugSorb-ATR, an antithrombotic removal system; VetResQ, a broad-spectrum blood purification adsorber for the treatment of septic shock, toxic shock syndrome, toxin-mediated diseases, pancreatitis, trauma, liver failure, heat stroke, and lung injury in animals; PuriFi, an advanced hemoperfusion pump for blood purification therapies; and ECOS-300CY, an ex vivo organ perfusion system to preserve or improve the health and quality of harvested solid organs to be transplanted.
In addition, it develops HemoDefend-BGA, a blood purification technology platform to reduce anti-A and anti-B antibodies in plasma and whole blood.
The company was formerly known as MedaSorb Technologies Corporation and changed its name to Cytosorbents Corporation in May 2010.
Cytosorbents Corporation was founded in 1997 and is headquartered in Princeton, New Jersey.
| Country | United States |
| Founded | 1997 |
| Industry | Medical Devices |
| Sector | Healthcare |
| Employees | 149 |
| CEO | Phillip Chan |
Contact Details
Address: 305 College Road East Princeton, New Jersey 08540 United States | |
| Phone | 732 329 8885 |
| Website | cytosorbents.com |
Stock Details
| Ticker Symbol | CTSO |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001175151 |
| CUSIP Number | 23283X206 |
| ISIN Number | US23283X2062 |
| Employer ID | 98-0373793 |
| SIC Code | 3841 |
Key Executives
| Name | Position |
|---|---|
| Dr. Phillip P. Chan M.D., Ph.D. | Chief Executive Officer and Director |
| Vincent J. Capponi M.S. | President and Chief Operating Officer |
| Kathleen P. Bloch CPA, M.B.A. | Advisor |
| Dr. Efthymios N. Deliargyris FACC, FESC, FSCAI, M.D. | Chief Medical Officer |
| Peter J. Mariani CPA | Chief Financial Officer |
| Dr. Christian Steiner M.D. | Executive Vice President of Sales and Marketing |
| Christopher Cramer M.B.A., M.S. | Senior Vice President of Business Development |
| Jodi Hoover | Executive |
| Dr. Robert H. Bartlett M.D. | Co-Chairman of Cardiac Surgery Advisory Board and Consultant |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Apr 23, 2025 | ARS | Filing |
| Apr 23, 2025 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Apr 23, 2025 | DEF 14A | Other definitive proxy statements |
| Apr 17, 2025 | 8-K | Current Report |
| Apr 17, 2025 | SCHEDULE 13G | Filing |
| Apr 15, 2025 | 8-K | Current Report |
| Apr 4, 2025 | 8-K | Current Report |
| Mar 31, 2025 | 8-K | Current Report |
| Mar 31, 2025 | 10-K | Annual Report |
| Mar 31, 2025 | 8-K | Current Report |